文献速递肾血管病与高血压急性肾损伤慢性肾脏病

单侧肾切除术后使用肾素-血管紧张素系统阻滞剂的肾脏结局

Renal Outcomes With Renin-Angiotensin System Blockers After Unilateral Nephrectomy.
PubMed 文献 · Kidney Int Rep · 2024-10-10

这项单中心回顾性队列研究纳入580例2010至2020年间接受择期单侧肾切除术且术前已患高血压并服用降压药的患者,按术后是否使用RAS阻滞剂分组。结果显示术后立即使用RAS阻滞剂未影响1个月时的肾脏适应,也未增加高钾血症风险,且与更好的无透析生存相关。

要点

  • 单侧肾切除术后立即使用RAS阻滞剂不损害肾脏适应。
  • RAS阻滞剂使用未增加术后1年内高钾血症发生率。
  • RAS阻滞剂与更好的无透析生存相关(校正HR 0.531)。

核心结论

  • 单侧肾切除术后立即使用RAS阻滞剂未恶化肾脏适应或增加高钾血症,且与改善终末期肾病和死亡预后相关。

研究设计与样本

  • 单中心回顾性队列研究,纳入580例2010至2020年间接受择期单侧肾切除术且术前有高血压并服用降压药的患者。

主要发现

  • RAS阻滞剂组与对照组1个月时肾脏适应无差异(67.1% vs 66.8%;P=0.711)。
  • 两组术后1年内高钾血症发生率无差异。
  • RAS阻滞剂使用与更好的无透析生存相关(校正HR 0.531;95%CI 0.329-0.857;P=0.010)。

临床怎么用

  • 对于单侧肾切除术后合并高血压的患者,可考虑立即使用RAS阻滞剂而不必担心肾脏适应受损或高钾血症风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite the benefits of renin-angiotensin system (RAS) blockers, their immediate use after nephrectomy has been limited because of concerns about impaired renal adaptation. We aimed to evaluate the effect of RAS blockers immediately after unilateral nephrectomy on renal adaptation. METHODS: This single-center retrospective cohort study included 580 patients who underwent elective unilateral nephrectomy between 2010 and 2020 and had preexisting hypertension with antihypertensive medications. Patients were divided into groups according to the postnephrectomy RAS blocker use. The primary outcome was renal adaptation defined as (postnephrectomy estimated glomerular filtration rate [eGFR] ÷ prenephrectomy eGFR) × 100 at 1 month after surgery. Secondary outcomes included hyperkalemia during the first year and mortality or end-stage kidney disease within 3 years. RESULTS: The mean age was 65.2 years, 406 (70%) were male, and 308 (53.1%) received RAS blockers after nephrectomy. The RAS blocker group was younger (63.8 vs. 66.8 years) and had a higher eGFR (79.4 vs. 75.5 ml/min per 1.73 m2) than the control group. There were no differences between the groups in renal adaptation at 1 month (67.1% vs. 66.8%; P = 0.711) or in the incidence of hyperkalemia until 1 year postoperatively. The RAS blocker use was associated with better dialysis-free survival (Adjusted hazard ratio of multivariable Cox-regression model: 0.531; 95% confidence interval: 0.329-0.857; P = 0.010]. CONCLUSION: The immediate use of RAS blockers after unilateral nephrectomy did not deteriorate renal adaptation or increase hyperkalemia. Furthermore, the RAS blockers were associated with improved prognosis in terms of end-stage kidney disease and mortality.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Lee S, Yoon S, Kim S, et al. Renal Outcomes With Renin-Angiotensin System Blockers After Unilateral Nephrectomy. Kidney Int Rep. 2024. PMID: 39810785. doi:10.1016/j.ekir.2024.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。